NASDAQ
98.99USD
-0.76 (-0.76%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
19.8B
P/E
—
EPS
—
Beta
0.79
52W range
66.74-112.29
Day range
98.26–101.02
Open
99.82
Prev close
99.75
Volume
1.7M
Avg volume
1.6M
Dividend
0.00
IPO
1993-11-04
https://www.businesswire.com/news/home/20260613021335/en/Incyte-Announces-New-Positive-Data-at-EHA-2026-Showed-INCA033989-Achieved-Rapid-Robust-and-Sustained-Clinical-and-Molecular-Responses-and-Was-Well-Tolerated-in-Patients-with-Myelofibrosis-and-Essential-Thrombocythemia/ · 6/13/2026+1.00
https://seekingalpha.com/article/4913582-incyte-i-am-moving-from-hold-to-buy · 6/10/2026+0.80
https://www.reuters.com/legal/transactional/incyte-nears-up-2-billion-deal-blood-disorder-biotech-star-ft-reports-2026-06-07/ · 6/7/2026+0.30
https://www.marketbeat.com/instant-alerts/incyte-ceo-says-post-jakafi-growth-path-is-clearer-as-pipeline-catalysts-build-2026-05-18/ · 5/18/2026+0.80
https://www.prnewswire.com/news-releases/new-first-in-class-therapy-for-chronic-graft-versus-host-disease-approved-in-australia1-302760088.html · 5/3/2026+1.00
https://www.businesswire.com/news/home/20260501334677/en/Incyte-Announces-FDA-Approval-of-Jakafi-XR%E2%84%A2-ruxolitinib-Extended-Release-Tablets-for-the-Treatment-of-Myelofibrosis-Polycythemia-Vera-and-Graft-Versus-Host-Disease/ · 5/1/2026+1.00
https://www.zacks.com/stock/news/2907296/incyte-gears-up-to-report-q1-earnings-what-can-investors-expect?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2907296 · 4/24/2026+0.40
https://www.businesswire.com/news/home/20260325544544/en/Incyte-Announces-Executive-Leadership-Appointments/ · 3/25/2026+0.10
https://seekingalpha.com/article/4884836-incyte-an-undervalued-healthcare-gem · 3/23/2026+0.80
https://seekingalpha.com/article/4883127-incyte-valued-like-a-single-drug-company-despite-diversifying-revenue · 3/17/2026+0.80
https://seekingalpha.com/article/4882856-incyte-stock-multiple-potential-catalysts-in-2026-and-beyond · 3/16/2026+0.60
https://www.zacks.com/stock/news/2881109/incy-wins-ec-approval-for-label-expansion-of-oncology-drug-zynyz?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2881109 · 3/9/2026+1.00
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works